High TCR Degeneracy Enhances Antiviral Efficacy of HTLV-1-Specific CTLs by Targeting Variant Viruses in HAM Patients
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26146602 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Ryuji Kubota und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Neuroimmunology, Joint Research Center for Human Retrovirus Infection, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima 890-8544, Japa…. Hauptthemen laut MEDLINE: T-Lymphocytes, Cytotoxic, Human T-lymphotropic virus 1, Receptors, Antigen, T-Cell, Paraparesis, Tropical Spastic. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan, Ministry of Education, Culture, Sports, Science and Technology of Japan.
Abstract (Originalsprache)
T-cell receptors (TCRs) exhibit degeneracy, enabling individual TCRs to recognize multiple altered peptide ligands (APLs) derived from a single cognate antigen. This characteristic has been involved in the pathogenesis of autoimmune diseases through cross-reactivity between microbial and self-antigens. Cytotoxic T lymphocytes (CTLs), which recognize peptide–MHC class I complexes via TCRs, play a critical role in the immune response against viral infections. However, the extent to which TCR degeneracy within a population of virus-specific CTLs contributes to effective viral control remains poorly understood. In this study, we investigated the magnitude and functional relevance of TCR degeneracy in CTLs targeting an immunodominant epitope of human T-cell leukemia virus type 1 (HTLV-1) in patients with HTLV-1-associated myelopathy (HAM). Using peripheral blood mononuclear cells (PBMCs) from these patients, we quantified TCR degeneracy at the population level by comparing CTL responses to a panel of APLs with responses to the cognate epitope. Our findings demonstrated that increased TCR degeneracy, particularly at the primary TCR contact residue at position 5 of the antigen, was inversely correlated with HTLV-1 proviral load (p = 0.038, R = −0.40), despite similar functional avidity across patient-derived CTLs. Viral sequencing further revealed that CTLs with high TCR degeneracy exerted stronger selective pressure on the virus, as indicated by a higher frequency of nonsynonymous substitutions within the epitope-encoding region in patients with highly degenerate TCR repertoires. Moreover, TCR degeneracy was positively correlated with the recognition rate of epitope variants (p = 0.018, R = 0.76), suggesting that CTLs with high TCR degeneracy exhibited enhanced recognition of naturally occurring epitope variants compared to those with low TCR degeneracy. Taken together, these results suggest that virus-specific CTLs with high TCR degeneracy possess superior antiviral capacity, characterized by broadened epitope recognition and more effective suppression of HTLV-1 infection. To our knowledge, this is the first study to systematically quantify TCR degeneracy in HTLV-1-specific CTLs and evaluate its contribution to viral control in HAM patients. These findings establish TCR degeneracy as a critical determinant of antiviral efficacy and provide a novel immunological insight into the mechanisms of viral suppression in chronic HTLV-1 infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Neuroimmunology, Joint Research Center for Human Retrovirus Infection, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima 890-8544, Japan.
- Department of Bioscience and Bioinformatics, Kyushu Institute of Technology, 680-4 Kawazu, Iizuka-shi 820-8502, Japan.
- Department of Microbiology, Kawasaki Medical School, 577 Matsushima, Kurashiki 701-0192, Japan.
- Department of Neurology and Geriatrics, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima 890-8520, Japan.
ORCID-Profile: Ryuji Kubota, Mineki Saito, Satoshi Nozuma
Förderung
- Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan
- Ministry of Education, Culture, Sports, Science and Technology of Japan
Zitieren
APA
Kubota, R., Hanada, K., Saito, M., Dozono, M., Nozuma, S., & Takashima, H. (2025). High TCR Degeneracy Enhances Antiviral Efficacy of HTLV-1-Specific CTLs by Targeting Variant Viruses in HAM Patients. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26146602
Vancouver
Kubota R, Hanada K, Saito M, Dozono M, Nozuma S, Takashima H. High TCR Degeneracy Enhances Antiviral Efficacy of HTLV-1-Specific CTLs by Targeting Variant Viruses in HAM Patients. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26146602
BibTeX
@article{Kubota2025,
author = {Kubota, Ryuji and Hanada, Kousuke and Saito, Mineki and Dozono, Mika and Nozuma, Satoshi and Takashima, Hiroshi},
title = {High TCR Degeneracy Enhances Antiviral Efficacy of HTLV-1-Specific CTLs by Targeting Variant Viruses in HAM Patients},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26146602}
}
EUVIMED